Hormonal
Incretin stimulation via GLP-1 receptor agonists (e.g., liraglutide, exenatide) and DPP-4 inhibitors reduces visceral and epicardial adipose tissue volume and thickness while promoting the browning of white adipocytes, thereby alleviating insulin resistance and associated cardiovascular pathologies in obese and type-2 diabetic patients.
For patients with obesity and Type-2 Diabetes, GLP-1 receptor agonists (like liraglutide) and DPP-4 inhibitors are effective pharmacological tools to specifically target dangerous visceral and epicardial fat. Unlike Metformin, these drugs significantly shrink epicardial fat thickness, which is linked to cardiovascular risk. This reduction in fat volume, combined with improved insulin sensitivity, offers a targeted approach to preventing heart disease in this population.
Furthermore, incretin stimulation reduced visceral and epicardial fat thickness whereas increased formation of brown adipocytes, alleviating insulin resistance and associated cardiovascular pathologies.
Why this rating
The paper is a review citing multiple clinical studies and meta-analyses showing consistent reductions in EAT/VAT and improvements in metabolic markers.
Source
Regulation of visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and diabetes
Nieves González et al. · Cardiovascular Diabetology · 2017
DOI 10.1186/s12933-017-0528-4
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →